30 Participants Needed

Exercise for Lung Cancer

(ENHANCE Trial)

DK
CD
Christina M Dieli-Conwright, PhD profile photo
Overseen ByChristina M Dieli-Conwright, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Dana-Farber Cancer Institute
Must be taking: Anti-PD-1, Anti-PD-L1
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how different types of exercise affect people with advanced lung cancer who are receiving immune checkpoint inhibitors, a type of cancer therapy. Participants will engage in either high-intensity interval training (short bursts of vigorous exercise) or moderate-intensity continuous training (steady-paced exercise) on a stationary bike. The researchers aim to determine if one type of exercise offers more benefits than the other. This trial targets individuals with advanced non-small cell lung cancer who currently engage in minimal exercise and have a doctor's approval for physical activity. As an unphased trial, it provides a unique opportunity to contribute to understanding how exercise can enhance cancer treatment outcomes.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, you must have been receiving anti-PD-1 or anti-PD-L1 antibodies for at least one month and plan to continue them for at least 12 weeks.

What prior data suggests that these exercise programs are safe for individuals with advanced lung cancer?

Research has shown that High-Intensity Interval Training (HIIT) is safe and well-tolerated for people with cancer. One study found that HIIT helped lung cancer patients experience fewer lung problems after surgery, with a low risk of side effects while improving health. Another review of several studies confirmed that HIIT improved fitness in cancer patients with minimal negative effects.

For Moderate-Intensity Continuous Training (MICT), studies have shown it improves fitness and quality of life in lung cancer patients. Specifically, one study found that exercise programs like MICT were safe and beneficial for overall health. Both HIIT and MICT have shown promise in enhancing physical health with minimal risk, making them good options for those considering joining exercise-based clinical trials.12345

Why are researchers excited about this trial?

Researchers are excited about these exercise protocols for lung cancer because they explore how different intensities of exercise can impact patients' health. High-Intensity Interval Training (HIIT) uses short bursts of vigorous exercise followed by recovery periods, which may improve cardiovascular fitness and overall endurance more efficiently than traditional methods. Moderate-Intensity Continuous Training (MICT), on the other hand, provides a steady exercise approach that balances intensity and duration, potentially benefiting those who prefer a less intense but consistent workout. Unlike conventional treatments that focus on medication or surgery, these exercise protocols aim to enhance quality of life and physical performance, offering a complementary approach to existing care.

What evidence suggests that this trial's exercise programs could be effective for lung cancer?

This trial will compare High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MICT) for lung cancer patients. Studies have shown that HIIT can significantly enhance lung function in these individuals. Specifically, research indicates that HIIT increases both VO2peak, which measures the body's oxygen usage, and FEV1, which measures the volume of air exhaled. Additionally, patients who participated in HIIT reported feeling better after 12 weeks. Meanwhile, MICT has effectively reduced cancer-related fatigue and improved overall quality of life for lung cancer patients. Both exercise types show promise in enhancing well-being and fitness levels for these patients.12456

Who Is on the Research Team?

CD

Christina Dieli-Conwright, PhD, MPH

Principal Investigator

Dana-Farber Cancer Institute

Are You a Good Fit for This Trial?

The INHALE Trial is for adults over 18 with advanced lung cancer who are on single-agent anti-PD-1 or anti-PD-L1 immunotherapy and can exercise safely. They should do less than 60 minutes of moderate-to-vigorous exercise weekly, not be on other systemic treatments like chemo, and must understand English.

Inclusion Criteria

You have been doing less than 60 minutes of moderate-to-intense exercise per week for the past month.
I have been diagnosed with metastatic non-small cell lung cancer.
I do not have any health conditions that get worse with exercise.
See 6 more

Exclusion Criteria

I do not have another cancer that needs treatment at the same time as this study.
I am not on any other systemic treatments for NSCLC besides anti-PD-1/PD-L1.
You have been doing more than 60 minutes of moderate-to-vigorous exercise each week for the past month. This study is for people who don't exercise much, so if you've been doing more exercise, it might affect the study results.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo 12 weeks of exercise training at different intensities while receiving immune checkpoint inhibitors

12 weeks
3 sessions per week (virtually supervised)

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks

Open-label extension (optional)

Participants in the Usual Care group may opt into the exercise program after the initial 12 weeks

12 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • High-Intensity Interval Training
  • Moderate-Intensity Continuous Training
Trial Overview This study tests if a home-based, virtually supervised 12-week exercise program is workable and beneficial for lung cancer patients on immunotherapy. It compares high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), and usual care.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Active Control
Group I: Moderate-Intensity Continuous Training (MICT)Experimental Treatment1 Intervention
Group II: High-Intensity Interval Training (HIIT)Experimental Treatment1 Intervention
Group III: Usual Care (UC)Active Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Dana-Farber Cancer Institute

Lead Sponsor

Trials
1,128
Recruited
382,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Published Research Related to This Trial

A randomized trial involving 151 patients with operable lung cancer found that preoperative high-intensity interval training (HIIT) rehabilitation did not lead to significant improvements in pulmonary function or aerobic capacity one year after surgery.
Both the rehabilitation group and the usual care group showed similar reductions in peak oxygen uptake and peak work rate, indicating that the short-term HIIT intervention did not enhance long-term postoperative outcomes.
Short-term preoperative exercise therapy does not improve long-term outcome after lung cancer surgery: a randomized controlled study.Karenovics, W., Licker, M., Ellenberger, C., et al.[2022]
Maximal-intensity aerobic interval training (MAIT) significantly improved maximal oxygen uptake (O2max) by 31% in patients with acute coronary syndrome, compared to a 17% increase with high-intensity aerobic interval training (HAIT), indicating that MAIT may be more effective for enhancing cardiovascular fitness.
Both MAIT and HAIT were found to be safe, with no major cardiovascular or musculoskeletal complications reported during the 6-week training period, suggesting their suitability for cardiac rehabilitation.
The Effect and Safety of Aerobic Interval Training According to Exercise Intensity in Acute Coronary Syndrome.Kim, C., Choi, HE.[2021]
High-intensity interval training (HIIT) significantly improves cardiorespiratory fitness (measured as peak V̇O2) in cancer patients and survivors compared to usual care, with a mean difference of 2.11 ml kg-1 min-1.
HIIT shows similar effectiveness to moderate-intensity continuous training (MICT) in improving peak V̇O2, while also demonstrating better adherence rates (71.2% to 95.6%) and no serious adverse events reported.
High-intensity interval training improves cardiorespiratory fitness in cancer patients and survivors: A meta-analysis.Wallen, MP., Hennessy, D., Brown, S., et al.[2021]

Citations

Functional and postoperative outcomes after high-intensity ...With regard to pulmonary function, our results showed that both VO2peak and FEV1 improved with the application of HIIT among lung cancer patients.
Clinical updates on the effects of high intensity interval ...Comprehensive meta-analysis of 35 trials (n = 1893 participants) using HIIT showed significant improvements across several physical outcomes in the cancer ...
Effects of high-intensity interval training (HIIT) versus ...This study primarily found that HIIT improved cardiopulmonary health in cancer survivors compared to the MICT group. This finding is consistent ...
High intensity interval training safety and efficacy in ...Patients in the exercise group demonstrated a significant improvement at 12 weeks in the Lung Cancer Symptoms domain on 28 points (22.3 vs 19.8, p = 0.015) as ...
Effectiveness of HIIT in patients with cancer or ...HIIT training seemed to be effective to improve cardiorespiratory fitness in cancer survivors. However, during active treatment, there were contrasting results.
High-intensity interval training in the prehabilitation of cancer ...Furthermore, HIIT was feasible and safe, showing low risk of adverse events and positive effects on health-related outcomes in prehabilitative settings.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security